Age and Diabetes Mellitus Associated with Hematological Disorders and Peripheral Neuropathy in MDR-TB Patients Treated with the BPaL/M Regimen
Abstract
Introduction: Tuberculosis (TB) is a disease with a significant treatment burden. Current multidrug-resistant (MDR)-TB therapy uses the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL/M) combination. This combination is effective with a short treatment duration. Linezolid is one of the components of the BPaL/M regimen. However, despite its effectiveness, it has side effects that impact treatment management and success. This study aimed to find the association between characteristics and comorbidities with the incidence of linezolid side effects in patients with MDR-TB treated with the BPaL/M regimen.
Methods: This was a retrospective analytic study of MDR-TB patients receiving BPaL/M combination. Data were collected from medical records and analyzed using Fisher's exact test to analyze the association between patient characteristics and comorbidities with the incidence of linezolid side effects, namely hematological disorders, peripheral neuropathy, and visual disturbances.
Results: There was no significant association between overall patient characteristics and the incidence of linezolid adverse events. However, the results of bivariate analysis showed a significant association in age >50 years old with the incidence of hematological disorders, as well as in patients who have diabetes mellitus (DM) with the incidence of peripheral neuropathy as a side effect of linezolid.
Conclusion: Monitoring of MDR-TB patients aged >50 years old and those with DM to minimize…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.